Public Health Update with the Indiana Department of Health - February 2, 2022
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Public Health Update with the Indiana Department of Health February 2, 2022
Agenda
• Opening Remarks
• Housekeeping
• Presentation
• Q&A
• Closing Remarks
2
Who We Are
Qsource has more than 45
years of experience working
with with healthcare providers,
Medicare and Medicaid.
Currently operate in 11 states
overseeing ESRD, EQRO and
QIO activities.
Serves as the Medicare Quality
Innovation Network-Quality
Improvement Organization
(QIN-QIO) for Indiana.
3
Housekeeping Items: Chat
• To ensure maximum sound quality, participant lines have
been muted during the presentation; however, we welcome
questions and comments via the chat box on the right-hand
side of your screen
• During the Q&A portion of the presentation, we will unmute
your lines.
• To submit questions or comments:
• Use the chat box or,
• Raise your hand to verbally ask your question
4
Polling Question
In which setting do you work?
A. Long Term Care
B. Hospital
C. Home Health
D. Community-Based Organization
E. Other
5
PUBLIC HEALTH UPDATES PAM PONTONES, MA DEPUTY STATE HEALTH COMMISSIONER STATE EPIDEMIOLOGIST 02/02/2022
Omicron is different from previous variants
CDC MMWR: Vaccine vs Unvaccinated
• Using over eight months of data in 2021 from 25 states, investigators reviewed
changes in rates of COVID-19 cases (April 4–December 25, 2021) and associated
deaths (April 4–December 4, 2021) by vaccination status, including receipt of
boosters. Investigators assessed rates before and during the Delta period as well as
during the emergence of Omicron.
• In 2021, compared with fully vaccinated people overall (received a primary series),
unvaccinated people had
o 14 times the risk of infection pre-Delta (April–May)
o 9 times the risk of infection as Delta emerged (June)
o 5 times the risk of infection during Delta’s predominance (July–November)
o More than 15 times the risk of death before and after Delta emerged (relatively stable
during July–November)
https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e2.htm?s_cid=mm7104e2_e&ACSTrackingID=USCDC_921-
DM73911&ACSTrackingLabel=MMWR%20Early%20Release%20-
%20Vol.%2071%2C%20January%2021%2C%202022&deliveryName=USCDC_921-DM73911 -
Rates of COVID-19 Cases and Deaths by Vaccination Status
https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status
CDC MMWR: Vaccine and boosted vs Unvaccinated during Delta
• Comparing unvaccinated people and fully vaccinated people by receipt of
booster doses during the period of Delta variant predominance (October–
November 2021)
• Compared with fully vaccinated people without a booster, unvaccinated
adults had
o 4 times the risk of infection with the virus that causes COVID-19
o 13 times the risk of COVID-19-associated deaths
• Compared with fully vaccinated adults with a booster, unvaccinated adults
had
o 14 times the risk of infection with the virus that causes COVID-19
o More than 50 times the risk of COVID-19-associated deaths
https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e2.htm?s_cid=mm7104e2_e&ACSTrackingID=USCDC_921-
DM73911&ACSTrackingLabel=MMWR%20Early%20Release%20-
%20Vol.%2071%2C%20January%2021%2C%202022&deliveryName=USCDC_921-DM73911CDC MMWR: Vaccine and boosted vs Unvaccinated during Omicron
Comparing unvaccinated people and fully vaccinated people by
receipt of booster doses during the period of Omicron variant
emergence (December 2021)
• Compared with fully vaccinated adults with a booster, unvaccinated adults
had 5 times the risk of infection with the virus that causes COVID-19
• Compared with fully vaccinated people without a booster, unvaccinated
adults had 3 times the risk of infection with the virus that causes COVID-19
https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e2.htm?s_cid=mm7104e2_e&ACSTrackingID=USCDC_921-
DM73911&ACSTrackingLabel=MMWR%20Early%20Release%20-
%20Vol.%2071%2C%20January%2021%2C%202022&deliveryName=USCDC_921-DM73911Moderna Vaccine Gets Full FDA Approval
• U.S. Food and Drug Administration gave full approval
Jan. 31 to Moderna vaccine for 18 and older
• New vaccine is branded as Spikevax
• Same formulation as the EUA Moderna
• Used as primary series of two doses
• Full approval is another signal of confidence in the
vaccine’s safety and efficacy
https://www.fda.gov/news-events/press-
announcements/coronavirus-covid-19-update-fda-
takes-key-action-approving-second-covid-19-vaccineNovavax Submits Request to FDA
• Protein-based vaccine engineered from the genetic sequence of
the first strain of SARS-CoV-2
• Ages 18 and older
• The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen
and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days
apart.
• Stored at 2°- 8° Celsius
• Studying third dose and ages 12-17
• More information on trials published in New England Journal of
Medicine:
https://www.nejm.org/doi/full/10.1056/NEJMoa2116185?query=featured_home
https://ir.novavax.com/2022-01-31-Novavax-Submits-Request-
to-the-U-S-FDA-for-Emergency-Use-Authorization-of-COVID-
19-VaccinePfizer Submits Request to FDA • Submitted request to FDA for EUA for 2-dose vaccine for those 6 months-
COVID and Influenza
Week ending ILI percentage from ILI percentage from Percentage of flu
sentinel syndromic positive specimens
tested at IDOH
December 11 2.25% 2.28% 17% (5+ of 29
specimens)
December 18 2.57% 2.43% 31% (9+ of
29 specimens)
December 25 3.05% 3.00% 0% (8 specimens)
January 1 3.24% 3.32% 44% (4+ of 9 specimens)
January 8 2.81% 2.76% 25% (1+ of 4 specimens)
January 15 2.65% 2.62% 0% (8 specimens)
January 22 2.07% 2.04% 0% (4 neg, 1 unsat)
https://www.in.gov/health/erc/infectious-disease-epidemiology/diseases-
and-conditions-resource-page/weekly-influenza-reportsPneumonia Vaccines
• Vaccines help prevent pneumococcal disease, which is any type of illness caused by Streptococcus
pneumoniae bacteria
• Two kinds of pneumococcal vaccines available in the United States:
• Pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20)
• Pneumococcal polysaccharide vaccine (PPSV23)
• You can get a COVID-19 vaccine and other vaccines, including a flu vaccine, at the same visit
• Experience with other vaccines has shown that the way our bodies develop protection, known as an
immune response, and possible side effects after getting vaccinated are generally the same when given
alone or with other vaccines. Learn more about the timing of other vaccines
Frequently Asked Questions about COVID-19
Vaccination | CDC
16Latest Guidance
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-
Valent Pneumococcal Conjugate Vaccine Among U.S. Adults:
Updated Recommendations of the Advisory Committee on
Immunization Practices — United States, 2022 | MMWR
17
(cdc.gov)Summary of Recommendations
• CDC recommends PCV13 for:
• All babies and children younger than 2 years old
• Children 2 through 18 years old with certain medical conditions
• CDC recommends PCV15 or PCV20 for:
• Adults 65 years or older
• Adults 19 through 64 years old with certain medical conditions or risk factors
• CDC recommends PPSV23 for:
• Children 2 through 18 years old with certain medical conditions
• Adults 19 years or older who get PCV15
Pneumococcal Vaccination | CDC
18Other Updates and Numbers
Case Trend Cases during the omicron surge continue to trend in the younger age groups. Those 0- 39 make up about 60% of all current cases.
Case Trend by District
Cases Per Capita in Surrounding States
Cases by Type
Therapeutics Map Updated
https://www.coronavirus.in.gov/covid-19-treatment-information/Vaccinations by Week
County Metrics Last week: This week:
Hospital Census
Indiana’s COVID hospital census is still high but appears to have
peaked and is dropping. As of Jan. 27, Indiana reported 2,898 COVID
patients in the hospital. This is down from the omicron peak of 3,506
and the first time below 3,000 in a month.Hospitalizations by Age Group
Questions?
Pam Pontones, MA Shireesha
Deputy Health Vuppalanchi, MD
Commissioner Medical Director
State Epidemiologist Long-Term Care
Indiana Department of Division
Health Indiana Department of
ppontones@isdh.in.go Health
v svuppalanchi@isdh.in.
govThank you for joining us!
Please complete the survey link provided to you in the chat –
we value your feedback in developing future events!
Please visit us at www.Qsource.org/qio
30Connect with Us Reminders
Facebook
www.facebook.com/QsourceLiveWell
Twitter
www.twitter.com/Qsource
LinkedIn
www.linkedin.com/in/qsource-healthcare-consultants
www.Qsource.org
This material was prepared by Qsource, a/an Network of Quality Improvement and Innovation Contractors under contract with the Centers for
Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this
31 material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not
constitute endorsement of that product or entity by CMS or HHS. 22.QIO.CLIN6.01.004You can also read
